PVI
FATE icon

Pura Vida Investments’s Fate Therapeutics FATE Stock Holding History

Pura Vida Investments’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,500
Closed -$2.84M – 248
2021
Q4 		$2.84M Sell
48,500
-1,500
-3% -$85K 0.1% 137
2021
Q3 		$2.96M Buy
+50,000
New +$3.92M 0.09% 172

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Pura Vida Investments's FATE Position: Q2 2018 in Review

Pura Vida Investments sold out of Fate Therapeutics (FATE) in Q2 2018, closing a stake of 59,600 shares — an estimated $582K sold.

Pura Vida Investments first reported a position in FATE in Q1 2018 and held it in 1 quarter. The position peaked at $582K in Q1 2018. 103 funds tracked by Wall St. Rank hold FATE as of Q2 2018.

  • Pura Vida Investments reported no remaining Fate Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Pura Vida Investments sold 59,600 Fate Therapeutics shares in Q2 2018, an estimated $582K.
  • Pura Vida Investments first reported a position in Fate Therapeutics in Q1 2018 and held it in 1 quarter.
  • Pura Vida Investments's Fate Therapeutics position peaked at $582K in Q1 2018.
  • 103 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2018.

Based on Pura Vida Investments's 13F filing for Q2 2018, filed 14 Aug 2018.